Immunome, Inc.
Immunome, Inc. (IMNM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IMNM · as of Mar 31, 2025
Ownership Breakdown
148
Institutional Holders
▲ 24 vs Q4
$518.45M
Total Inst. Value
▼ $47.87M vs Q4
95.60M
Shares Outstanding
freeFloat 82.90%
76.94M
13F Shares Held
▲ 23.63M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IMNM largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 7.55M | 9.51% | 9.51% | $50.84B | May 14, 2025 | ▲ 2.05M |
BLACKROCK, INC. pharmaceutical preparations | 5.66M | 7.13% | 7.13% | $38.11B | May 2, 2025 | ▲ 1.54M |
REDMILE GROUP, LLC pharmaceutical preparations | 5.36M | 6.75% | 6.75% | $36.08B | May 15, 2025 | ▲ 533.2K |
ENAVATE SCIENCES GP, LLC pharmaceutical preparations | 4.77M | 6.00% | 6.00% | $32.09B | May 15, 2025 | ▲ 1.29M |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.36M | 5.49% | 5.49% | $29.35B | Jul 21, 2025 | ▲ 3.67M |
VANGUARD GROUP INC pharmaceutical preparations | 4.31M | 5.42% | 5.42% | $28.99B | May 9, 2025 | ▲ 1.30M |
ECOR1 CAPITAL, LLC pharmaceutical preparations | 4.08M | 5.14% | 5.14% | $27.45B | May 15, 2025 | ▲ 200.0K |
FMR LLC pharmaceutical preparations | 3.89M | 4.90% | 4.90% | $26.20B | May 12, 2025 | ▼ 26.9K |
OPALEYE MANAGEMENT INC. pharmaceutical preparations | 3.55M | 4.47% | 4.47% | $23.89B | May 15, 2025 | ▲ 1.51M |
PRIMECAP MANAGEMENT CO/CA/ pharmaceutical preparations | 3.41M | 4.30% | 4.30% | $22.97B | May 9, 2025 | ▲ 3.13M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
36
Increased
+24.41M shares7
New Positions
first time holders6
Decreased
−1.70M shares0
Sold Out
fully exitedNet shares change (top 50)
+22.71M
+24.41M / −1.70M
Net new holders
+37
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IMNM insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
5
Sell transactions
0.40
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
BIENAIME JEAN JACQUES director | May 15, 2026 | Purchase | 5,000 | $20.70 | $103.5K | 43.4K | Form 4 ↗ |
Higgins Jack Chief Scientific Officer | Apr 2, 2026 | Sale | 9,438 | $21.64 | $204.2K | 22.0K | Form 4 ↗ |
Rosett Max Chief Financial Officer | Apr 2, 2026 | Sale | 63,656 | $21.91 | $1.39M | 55.4K | Form 4 ↗ |
Rosett Max Chief Financial Officer | Apr 2, 2026 | Sale | 1,344 | $22.48 | $30.2K | 54.0K | Form 4 ↗ |
Higgins Jack Chief Scientific Officer | Mar 30, 2026 | Gift | 6,291 | — | — | 31.4K | Form 4 ↗ |
SIEGALL CLAY B President and CEO | Mar 27, 2026 | Purchase | 25,450 | $19.67 | $500.6K | 690.7K | Form 4 ↗ |
WAGENHEIM PHILIP director | Mar 20, 2026 | Sale | 36,800 | $20.47 | $753.3K | 369.3K | Form 4 ↗ |
WAGENHEIM PHILIP director | Mar 23, 2026 | Sale | 28,200 | $20.65 | $582.3K | 341.1K | Form 4 ↗ |
BIENAIME JEAN JACQUES director | Mar 11, 2026 | Purchase | 1,000 | $21.55 | $21.6K | 38.4K | Form 4 ↗ |
BIENAIME JEAN JACQUES director | Mar 10, 2026 | Purchase | 1,000 | $22.12 | $22.1K | 37.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Immunome, Inc. (IMNM) is primarily owned by institutional investors, who hold approximately 80.5% of total shares outstanding. Company insiders own approximately 17.10%, while retail and public investors account for the remaining 2.41%.
The largest institutional shareholder of Immunome, Inc. is T. ROWE PRICE INVESTMENT MANAGEMENT, INC., holding approximately 7.55 million shares — equal to 9.51% of outstanding shares — as of March 31, 2025.
A total of 148 institutional investors currently hold IMNM stock, with a combined institutional value of approximately $518,449,526 as of the most recent 13F filing period.
Frequently asked questions
IMNM ownershipImmunome, Inc. (IMNM) is primarily owned by institutional investors, who hold approximately 80.5% of shares. The largest shareholder is T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with a 9.51% stake. Company insiders hold 17.10%. Data sourced from SEC Form 13F as of March 31, 2025.